Liver Metastasis at the Time of Initial Diagnosis of Lung Cancer

Kagohashi, Katsunori; Satoh, Hiroaki; Ishikawa, Hiroichi; Ohtsuka, Morio; Sekizawa, Kiyohisa

doi:10.1385/mo:20:1:25

Cited by 77 publications

(45 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, liver metastasis was an unfavorable prognostic factor in our study, which was consistent with previously reported results (3,5). Liver metastatic lesions are rarely associated with severe symptoms, although the majority of NSCLC patients had multiple nodules morphologically (17). It is well known that the majority of NSCLC patients with liver metastasis do not respond well to chemotherapy (18,19).…”

Section: Variablessupporting

confidence: 91%

Specific organ metastases and survival in metastatic non-small-cell lung cancer

Tamura

Kurishima

Nakazawa

et al. 2014

Molecular and Clinical Oncology

Self Cite

278

193

View full text Add to dashboard Cite

Abstract. The present retrospective study was performed to evaluate the clinicopathological characteristics associated with distant metastasis from non-small-cell lung cancer (NSCLC). The records of NSCLC patients with metastasis at the time of diagnosis between 1999 and 2012 were reviewed. Of the consecutive 1,542 NSCLC patients diagnosed during the study period, 729 (47.3%) patients presented with distant metastasis. Among those 729 metastatic NSCLC patients, 250 (34.3%), 234 (32.1%), 207 (28.4%), 122 (16.7%), 98 (13.4%) and 69 (9.5%) had bone, lung, brain, adrenal gland, liver and extrathoracic lymph node metastasis, respectively. In a multivariate analysis using the Cox proportional hazards model, liver and adrenal gland metastases were unfavorable prognostic factors. However, brain and bone metastases were not statistically significant prognostic factors. Using a logistic regression analysis, metastasis to the adrenal glands and the presence of pleural and̸or pericardial fluid effusion were correlated with a poor performance status. Therefore, when planning the treatment of NSCLC patients, particularly those with liver and adrenal gland metastases, we should take into consideration information regarding these unfavorable organ metastases.

show abstract

Section: Variablessupporting

confidence: 91%

Specific organ metastases and survival in metastatic non-small-cell lung cancer

Tamura

Kurishima

Nakazawa

et al. 2014

Molecular and Clinical Oncology

Self Cite

278

193

View full text Add to dashboard Cite

show abstract

“…The discontinuation of chemotherapy due to the deterioration of ADL in these patients has a certain correlation with poor survival. With regard to liver metastasis, the majority of SCLC patients had multiple nodules in our previous study (16). SCLC may cause biliary tract obstruction by metastasizing to lymph nodes in the porta hepatis or hepatic parenchyma (17,18).…”

Section: Discussionmentioning

confidence: 88%

Specific organ metastases and survival in small cell lung cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

Abstract. The aim of our retrospective study was to evaluate the clinicopathological features associated with distant metastasis from small cell lung cancer (SCLC). We reviewed patients diagnosed with SCLC metastasis at the time of presentation between 1999 and 2010. Among the consecutive 251 SCLC patients diagnosed, 152 (60.6%) patients had distant metastasis, of which 20.3, 18.3, 15.5, 10.0 and 6.0% of patients had liver, bone, brain, lung and adrenal gland metastasis, respectively. In a multivariate analysis using Cox's proportional hazards model, we identified that liver, bone and brain metastasis as well as the presence of pleural and/ or pericardial fluids were unfavorable prognostic factors. However, lung, adrenal gland and extrathoracic lymph node metastasis were not statistically significant prognostic factors. With regard to the treatment of SCLC patients, particularly those with liver, bone and brain metastasis or pleural and/or pericardial fluids, we should take the metastasizing organs into consideration.

show abstract

“…In addition to harboring primary tumors, the liver is often the target organ for metastatic lesions from colon (2), breast (3), or lung cancers (4). Unfortunately, treatment failure is frequent and results in high recurrence rates with short survival times (5-7).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But

Coradini

Zorzet

Rossin

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose:The purpose is to evaluate the CD44-mediated cellular targeting of HA-But, a hyaluronic acid esterified with butyric acid (But) residues, to hepatocellular carcinoma cell lines in vitro and to hepatic tumor metastases in vivo.Experimental Design: In vitro, the CD44-dependent cytotoxicity in two human hepatocellular carcinoma cell lines (HepB3 and HepG2) with high and low CD44 expression was investigated; in vivo, the effect on liver metastases originating from intrasplenic implants of Lewis lung carcinoma (LL3) or B16-F10 melanoma in mice was compared with the pharmacokinetics of organ and tissue distribution using different routes of administration.Results: HepB3 and HepG2 cell lines showed different expression of CD44 (78 and 18%, respectively), which resulted in a CD44-dependent HA-But inhibitory effect as demonstrated also by the uptake analysis performed using radiolabeled HA-But ( Conclusions: HA-But tends to concentrate in the liver and spleen and appears to be a promising new drug for the treatment of intrahepatic tumor lesions.

show abstract

Liver Metastasis at the Time of Initial Diagnosis of Lung Cancer

Cited by 77 publications

References 15 publications

Specific organ metastases and survival in metastatic non-small-cell lung cancer

Specific organ metastases and survival in metastatic non-small-cell lung cancer

Specific organ metastases and survival in small cell lung cancer

Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-But

Contact Info

Product

Resources

About